Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Change in Receivables (2016 - 2025)

Angiodynamics (ANGO) has disclosed Change in Receivables for 16 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables fell 58.01% year-over-year to $1.6 million, compared with a TTM value of $1.5 million through Nov 2025, up 120.04%, and an annual FY2025 reading of -$23000.0, up 99.71% over the prior year.
  • Change in Receivables was $1.6 million for Q4 2025 at Angiodynamics, up from -$139000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $10.7 million in Q2 2022 and bottomed at -$5.5 million in Q2 2024.
  • Average Change in Receivables over 5 years is $692150.0, with a median of $255000.0 recorded in 2021.
  • The sharpest move saw Change in Receivables skyrocketed 3858.33% in 2022, then tumbled 369.63% in 2024.
  • Year by year, Change in Receivables stood at $2.9 million in 2021, then crashed by 114.07% to -$406000.0 in 2022, then soared by 710.84% to $2.5 million in 2023, then soared by 50.56% to $3.7 million in 2024, then tumbled by 58.01% to $1.6 million in 2025.
  • Business Quant data shows Change in Receivables for ANGO at $1.6 million in Q4 2025, -$139000.0 in Q3 2025, and -$447000.0 in Q2 2025.